Analysts expect Becton Dickinson and Co (NYSE:BDX) to report sales of $4.11 billion for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Becton Dickinson and’s earnings, with the highest sales estimate coming in at $4.20 billion and the lowest estimate coming in at $4.06 billion. Becton Dickinson and posted sales of $3.08 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 33.4%. The company is expected to report its next earnings report on Tuesday, February 5th.
On average, analysts expect that Becton Dickinson and will report full year sales of $17.45 billion for the current fiscal year, with estimates ranging from $17.42 billion to $17.50 billion. For the next year, analysts expect that the firm will report sales of $18.38 billion, with estimates ranging from $18.26 billion to $18.48 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.93. The business had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.40 EPS.
A number of equities analysts have weighed in on the company. Deutsche Bank assumed coverage on Becton Dickinson and in a research note on Thursday. They issued a “buy” rating and a $280.00 target price on the stock. UBS Group assumed coverage on Becton Dickinson and in a research report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price objective on the stock. Citigroup reduced their price objective on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research report on Tuesday, November 13th. KeyCorp increased their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research report on Thursday, November 8th. Finally, Barclays set a $260.00 price objective on Becton Dickinson and and gave the company a “hold” rating in a research report on Thursday, November 8th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $255.53.
In related news, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the transaction, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Vincent A. Forlenza sold 16,866 shares of the firm’s stock in a transaction that occurred on Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total value of $4,007,530.26. The disclosure for this sale can be found here. Insiders have sold a total of 81,795 shares of company stock worth $19,571,318 over the last quarter. Corporate insiders own 1.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of BDX. Fundsmith Equity Fund L.P. bought a new position in Becton Dickinson and during the 2nd quarter worth approximately $894,775,000. FMR LLC grew its position in Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock worth $4,069,559,000 after acquiring an additional 2,049,874 shares during the last quarter. Morgan Stanley grew its position in Becton Dickinson and by 133.0% during the 3rd quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock worth $723,303,000 after acquiring an additional 1,581,829 shares during the last quarter. Charles Schwab Investment Advisory Inc. bought a new position in Becton Dickinson and during the 2nd quarter worth approximately $291,167,000. Finally, Vontobel Asset Management Inc. grew its position in Becton Dickinson and by 823.0% during the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock worth $250,205,000 after acquiring an additional 904,097 shares during the last quarter. Institutional investors and hedge funds own 85.19% of the company’s stock.
NYSE BDX traded down $6.00 during trading on Tuesday, reaching $234.44. The company’s stock had a trading volume of 1,180,108 shares, compared to its average volume of 1,017,171. The firm has a market capitalization of $62.89 billion, a P/E ratio of 21.29, a P/E/G ratio of 1.62 and a beta of 1.21. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90. Becton Dickinson and has a one year low of $209.91 and a one year high of $265.87.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 7th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 1.31%. Becton Dickinson and’s dividend payout ratio is 27.25%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What are different types of coverage ratios?
Get a free copy of the Zacks research report on Becton Dickinson and (BDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.